BFG
NRXP icon

Bleakley Financial Group’s NRX Pharmaceuticals NRXP Stock Holding History

Bleakley Financial Group’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$250K Hold
117,204
– – ﹤0.01% 731
2025
Q4 		$318K Buy
+117,204
New +$315K 0.01% 644

Other funds holding NRXP

BGI
B Group Inc Dallas, Texas $135M AUM 80% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
CPIG
Chicago Partners Investment Group Chicago, Illinois $4.48B AUM 19.29% 1-Year Est. Return

Bleakley Financial Group's NRXP Position: Q1 2026 in Review

Bleakley Financial Group held its NRX Pharmaceuticals (NRXP) position steady in Q1 2026 at 117,204 shares worth $250K. The position accounts for ﹤0.01% of the portfolio, ranked #731.

Bleakley Financial Group first reported a position in NRXP in Q4 2025 and has held it in 2 quarters since. The position peaked at $318K in Q4 2025. 33 funds tracked by Wall St. Rank hold NRXP as of Q1 2026.

  • Bleakley Financial Group held 117,204 shares of NRX Pharmaceuticals worth $250K as of Q1 2026.
  • Bleakley Financial Group left its NRX Pharmaceuticals share count unchanged in Q1 2026.
  • NRX Pharmaceuticals made up ﹤0.01% of Bleakley Financial Group's portfolio in Q1 2026, its #731 holding.
  • Bleakley Financial Group first reported a position in NRX Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Bleakley Financial Group's NRX Pharmaceuticals position peaked at $318K in Q4 2025.
  • 33 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q1 2026.

Based on Bleakley Financial Group's 13F filing for Q1 2026, filed 4 May 2026.